ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF) ...Middle East

SHANGHAI, May 15, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic pulmonary fibrosis (IPF). The study, led by Professor Huaping Dai of the...

Hence then, the article about arkbio announces positive phase ii results of ak3280 for treatment of idiopathic pulmonary fibrosis ipf was published today ( Friday 16/05/2025 - 04:03 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF) )

Also on site :

• French court denies extradition of ex-Tunisian President Ben Ali’s daughter
• Ford and Toyota issue major South African car recall
• ‘Like relying on a drug dealer:’ The world’s dependence on oil and gas has exposed a dangerous vulnerability